Pharmaron (03759) has announced that, in order to fully leverage the investment and research capabilities of professional investment institutions within the biopharmaceutical industry, its wholly-owned subsidiary Pharmaron UK Limited ("Pharmaron UK") intends to participate as a limited partner in HJ Double Helix Fund L.P. by subscribing to a capital contribution of US$10 million using its own or self-raised funds.
On November 6, 2026, Pharmaron UK signed the fund subscription documents, thereby subscribing to the limited partnership interest in the fund and becoming subject to the relevant terms of the fund's Amended and Restated Agreement of Exempted Limited Partnership of HJ Double Helix Fund L.P. while enjoying corresponding rights.
The partnership primarily makes equity and equity-related investments in the global biotechnology sector, with a focus on nucleic acid drugs, cell and gene therapies, as well as investment opportunities in their upstream and/or downstream industries.
Comments